{"nctId":"NCT00272792","briefTitle":"Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet","startDateStruct":{"date":"2006-02"},"conditions":["Phenylketonurias"],"count":45,"armGroups":[{"label":"Sapropterin Dihydrochloride","type":"EXPERIMENTAL","interventionNames":["Drug: Sapropterin Dihydrochloride"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Sapropterin Dihydrochloride","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of PKU with hyperphenylalaninemia (HPA) documented by at least one blood Phe measurement \\>/=360 umol/L (6 mg/dL)\n* Under dietary control with a Phe-restricted diet as evidenced by:· Estimated daily Phe tolerance \\</=1000 mg/day\n* At least 6 months of blood Phe control (mean level of \\</=480 μmol/L) prior to enrolling in the study\n* Aged 4 to 12 years inclusive at screening\n* A blood Phe level \\</=480 μmol/L at screening\n* Female subjects of childbearing potential (as determined by the principal investigator) must have a negative blood or urine pregnancy test at entry (prior to the first dose). Note: All female subjects of childbearing potential and sexually mature male subjects must be advised to use a medically accepted method of contraception throughout the study. Female subjects of childbearing potential must be willing to undergo periodic pregnancy tests during the course of the study\n* Willing and able to comply with all study procedures\n* Willing to provide written assent (if applicable) and written informed consent by a parent or legal guardian after the nature of the study has been explained and prior to any research-related procedures\n\nExclusion Criteria:\n\n* Any condition that, in the view of the PI, renders the subject at high risk from treatment compliance and/or completing the study\n* Prior history of organ transplantation\n* Perceived to be unreliable or unavailable for study participation or have parents or legal guardians who are perceived to be unreliable or unavailable\n* Use of any investigational agent within 30 days prior to screening, or requirement for any investigational agent or vaccine prior to completion of all scheduled study assessments\n* ALT \\> 2 times the upper limit of normal (i.e., Grade 1 or higher based on World Health Organization Toxicity Criteria) at screening\n* Concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin-dependent diabetes)","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"12 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Amount of Dietary Supplemented Phenylalanine (Phe)Tolerated in Children With Phenylketonuria","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":"15.4"},{"groupId":"OG001","value":"2.9","spread":"4.0"}]}]}]},{"type":"SECONDARY","title":"Change in Phenylalanine Levels From Baseline to Week 3","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-147.4","spread":"29.0"},{"groupId":"OG001","value":"-90.3","spread":"48.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":33},"commonTop":["Headache","Rhinorrhea","Cough","Pharyngolaryngeal Pain","Pyrexia"]}}}